Brind.

Corcept Therapeutics faces patent litigation with Teva, a situation that Joon Lee has questioned.

1 report, 1 independent Updated Aug 13

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Corcept Therapeutics Teva Pharmaceutical Industries Ltd.

Keep exploring

The entities involved

Corcept Therapeutics
American pharmaceutical company
- Corcept Therapeutics made required filings with the SEC regarding institutional holdings on June 16, 2026.Mon 03:27
Teva Pharmaceutical Industries Ltd.
Israeli pharmaceutical company
- Teva Pharmaceutical Industries Ltd. is being investigated by the Competition Authority regarding generic competition practices.Mon 13:16
- Leerink partners issued an 'outperform' rating on Teva stock, while an insider sold shares of the company.Wed 01:19

Related events

Teva's acquired product is currently undergoing review by the FDA.Aug 28

Coverage

Newest first; wire copies grouped

Aug 13StockStory5 Must-Read Analyst Questions From Corcept’s Q2 Earnings Call Corcept Therapeutics’ second quarter was marked by continued sales growth in its core endocrinology franchise, with management highlighti